Effect of glucocerebrosidase inhibition on intracellular α-synuclein oligomer formation and autophagic activity of dopaminergic cells

doi:10.3969/j.issn.1006-7795.2013.06.008

Abstract

Abstract:

Objective To investigate the effect of glucocerebrosidase (GBA) inhibition on intracellular α-synuclein(α-Syn) oligomer formation and autophagic activity of dopaminergic cells. Methods The activity of GBA was measured in MES 23.5 cells treated with different concentrations of CβE, the specific GBA inhibitor. After treatment with CβE, monomeric α-Syn was added into the medium and the amount of intracellular α-Syn oligomers were evaluated by ELISA. The autophagic activity, oxidative stress, and apoptotic cell counts were also examined. Results CβE dose-dependently decreased the activity of GBA and increased the levels of intracellular α-Syn oligomers. CβE also enhanced the autophagic activity, oxidative stress levels and apoptotic cell counts in an α-Syn concentration-dependent manner. Conclusion GBA inhibition causes intracellular accumulation of α-Syn oligomers and α-Syn concentration-dependent enhancement of autophagy, oxidative stress and apoptosis.

Key words: glucocerebrosidase, α-synuclein oligomer, MES 23.5 cells, autophagy

CLC Number:

R338

LIU Guangwei, YIN Na, MI Na, LI Xin, LI Yaohua, YU Shun. Effect of glucocerebrosidase inhibition on intracellular α-synuclein oligomer formation and autophagic activity of dopaminergic cells[J]. Journal of Capital Medical University, 2013, 34(6): 820-825.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2013.06.008

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2013/V34/I6/820

References

[1] Danzer K M, McLean P J. Drug targets from genetics: α-synuclein[J]. CNS Neurol Disord Drug Targets, 2011, 10(6):712-723.
[2] Li B, Zhang Y, Yuan Y, et al. A new perspective in Parkinson's disease, chaperone-mediated autophagy[J]. Parkinsonism Relat Disord, 2011, 17(4):231-235.
[3] Cookson M R. A feedforward loop links Gaucher and Parkinson's diseases?[J]. Cell, 2011, 146(1):9-11.
[4] Xilouri M, Vogiatzi T, Vekrellis K, et al. alpha-synuclein degradation by autophagic pathways: a potential key to Parkinson's disease pathogenesis[J]. Autophagy, 2008, 4(7):917-919.
[5] Sidransky E, Lopez G. The link between the GBA gene and parkinsonism[J]. Lancet Neurol, 2012, 11(11):986-998.
[6] Kong B, Yang T, Gu J W, et al. The association between lysosomal protein glucocerebrosidase and Parkinson's disease[J]. Eur Rev Med Pharmacol Sci, 2013, 17(2):143-151.
[7] Choi J H, Stubblefield B, Cookson M R, et al. Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations[J]. Mol Genet Metab, 2011, 104(1-2):185-188.
[8] Gegg M E, Burke D, Heales S J, et al.Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains[J]. Ann Neurol, 2012, 72(3):455-463.
[9] Goker-Alpan O, Stubblefield B K, Giasson B I, et al. Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders[J]. Acta Neuropathol, 2010, 120(5):641-649.
[10] Mak S K, McCormack A L, Manning-Bog A B, et al. Lysosomal degradation of alpha-synuclein in vivo[J]. J Biol Chem, 2010, 285(18):13621-13629.
[11] 殷娟娟, 韩俊燕, 李昕, 等.α-突触核蛋白功能片段向多巴胺能神经细胞内的转运及其对细胞增殖的影响[J].首都医科大学学报, 2007, 28(3):346-349.
[12] Park M J, Cheon S M, Bae H R, et al. Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-nave patients with Parkinson's disease[J]. J Clin Neurol, 2011, (4):215-222.
[13] Yu S, Li X, Liu G, et al. Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody[J]. Neuroscience, 2007, 145(2):539-555.
[14] Liu G, Wang P, Li X, et al. Alpha-synuclein promotes early neurite outgrowth in cultured primary neurons[J]. J Neural Transm, 2013, 120(9):1331-1343.
[15] Dice J F. Chaperone-mediated autophagy[J]. Autophagy, 2007, 3(4):295-299.
[16] Xilouri M, Brekk O R, Stefanis L. Alpha-synuclein and protein degradation systems: a reciprocal relationship[J]. Mol Neurobiol, 2013, 47(2):537-551.
[17] Yu W H, Dorado B, Figueroa H Y, et al. Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein[J]. Am J Pathol, 2009, 175(2):736-747.
[18] Gegg M E, Burke D, Heales S J, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains[J]. Ann Neurol, 2012, 72(3):455-463.